Cancer immunotherapy using in vitro genetically modified targeted dendritic cells

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Dendritic cell (DC) vaccines show limited clinical success, necessitating innovative strategies for cancer immunotherapy.
• Targeting tumor-associated antigens like ErbB2 is crucial for effective cancer vaccines.

Purpose of the Study:

• To develop and evaluate a novel chimeric receptor (CR) for enhancing DC vaccine efficacy against ErbB2-positive tumors.
• To assess the in vitro and in vivo performance of CR-modified DCs (scFv-CD40-DC).

Main Methods:

• Constructed a chimeric CD40 molecule with an ErbB2-specific single-chain variable fragment (scFv).
• Transferred the CR gene into bone marrow-derived DCs via adenoviral vector.
• Evaluated DC activation, migration, tumor inhibition, and immune responses in murine cancer models.

Main Results:

• CR-modified DCs exhibited nuclear factor-kappaB (NF-kappaB)-dependent activation and effector function.
• Approximately 40% of injected scFv-CD40-DCs migrated to ErbB2-positive tumors and draining lymph nodes.
• Significant inhibition of tumor growth and cure of established tumors were observed in murine models.
• Treated mice developed immunity against both ErbB2-positive and ErbB2-negative tumor rechallenge, indicating robust anti-tumor memory.

Conclusions:

• Genetic modification of DCs with an ErbB2-specific CD40 CR is a promising strategy for cancer immunotherapy.
• This approach induces potent, tumor-specific T-cell responses and long-lasting protective immunity.
• The scFv-CD40-DC therapy holds potential for treating human ErbB2-positive cancers.